Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNAJA4 divergent transcript (DNAJA4-DT) is a long noncoding RNA (lncRNA) species produced by divergent transcription from the promoter region of the DNAJA4 gene, a member of the DnaJ Heat Shock Protein Family (Hsp40)[3][4]. Divergent transcription is a widespread phenomenon in mammalian genomes, where RNA polymerase II initiates transcription in both sense and antisense orientations at active promoter or enhancer regions, resulting in the formation of lncRNAs or antisense RNAs alongside protein-coding transcripts[1][5]. DNAJA4-DT does not encode a protein and its biological function is poorly characterized, though similar divergent transcripts have been proposed to play roles in transcriptional regulation, chromatin architecture, and potentially in evolutionary gene origination[1]. Its expression is generally low and unstable, and subject to exosome-mediated RNA decay[5]. There are no known disease associations, drug interactions, or biomarker roles currently validated for DNAJA4-DT. The molecule is best classified as a regulatory noncoding RNA, distinguished from canonical druggable targets such as receptors, enzymes, or ion channels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNAJA4 divergent transcript (DNAJA4-DT).